Latest News
-
Watson in talks to buy Actavis
Watson Pharmaceuticals is currently in talks to buy private Swiss generic drug maker Actavis.
Latest News | 11 May 2012
-
UCB, Domainex Collaborates
Working together, the two companies have developed an experimental system to study the three-dimensional structure of Mitogen-activated protein kinase kinase (MAPKK, also known as MEK), a protein which is over-active in many human cancers.
Latest News | 10 May 2012
-
Siro Clinpharm appoints chief executive officer
Siro Clinpharm announced the appointment of Gopakumar Menon as chief executive officer.
Latest News | 09 May 2012
-
Kuehne + Nagel launches innovative airfreight solution for pharmaceutical products
KN PharmaChain offers – among other features – door-to-door temperature control, a 24 hour alert system, optional wireless temperature measuring and best practice (GxP) standards for facilities, working processes and training programmes.
Latest News | 08 May 2012
-
Bayer HealthCare, Tsinghua University in partnership
Both partners signed a new strategic agreement to collaborate in the area of biomedical sciences over the next three years.
Latest News | 07 May 2012
-
Telormedix’s TMX-101 exhibits high safety in phase I/II for non-muscle invasive bladder cancer
Telormedix announced that it has successfully completed the safety portion of a Phase I/II trial for TMX-101.
Latest News | 04 May 2012
-
Phosphagenics signs agreement with Nippon Zoki
The companies have struck a material transfer agreement which enables Nippon Zoki to test and assess Phosphagenics’ patented TPM/diclofenac topical non-steroidal pain formulation for its suitability as a prescription item in the USA and Japanese markets.
Latest News | 03 May 2012
-
Aslan Pharmaceuticals selects PharmaNet/i3 as partner for oncology development
Aslan Pharmaceuticals has selected PharmaNet/i3 as a partner supporting the development of their oncology portfolio in Asia.
Latest News | 02 May 2012
-
More investment needed in anti-obesity drugs
Pharmaceutical companies should increase their investment in anti-obesity drug therapies to support the growing number of clinically obese individuals worldwide, a report by GlobalData has found.
Latest News | 01 May 2012
-
INCIVEK is well tolerated with commonly used Atripla- and Reyataz-based HIV treatment regimens
Phase 2 study of INCIVEK combination regimen shows 74 percent of people co-infected with hepatitis C, HIV had undetectable hepatitis C virus 12 weeks after treatment ended.
Latest News | 30 April 2012
